Hence, in this real-world data (RWD)-based cohort study, we aim to evaluate differential risks of infections focusing on respiratory and urogenital systems associated with DPP-4 inhibitors and SGLT-2 inhibitors as compared to metformin therapy in insulin-treated diabetic patients with progressed T2DM states. This evidence concerns the gene INS and type 2 diabetes mellitus.